Abrdn Life Sciences Investors

HQL

US87911K1007

Closed End Funds

Market Closed - Nyse Other stock markets 21:00:02 16/05/2024 BST			5-day change	1st Jan Change
14.27 ^USD	+0.07%		+3.26%	+6.02%

2023	Tekla Life Sciences Investors Insider Bought Shares Worth $125,116, According to a Recent SEC Filing	MT
2023	Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund and Tekla Healthcare Investors Approves Election of Rose Dimartino, C. William Maher, Todd Reit and Stephen Bird as New Trustees	CI

Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2019

June 05, 2019 at 07:42 pm

Tekla Life Sciences Investors announced earnings results for the half year ended March 31, 2019. For the half year, the company announced total revenue was USD 1.126 million. Net loss was USD 39.103 million.

Latest news about Abrdn Life Sciences Investors

Tekla Life Sciences Investors Insider Bought Shares Worth $125,116, According to a Recent SEC Filing	25/09/23	MT
Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund and Tekla Healthcare Investors Approves Election of Rose Dimartino, C. William Maher, Todd Reit and Stephen Bird as New Trustees	22/08/23	CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 29, 2023	15/08/23	CI
Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2023	06/06/23	CI
Tekla Life Sciences Investors Declares Distribution, Payable on June 30, 2023	15/05/23	CI
Tekla Life Sciences Investors announces an Equity Buyback for 12% of its outstanding shares.	17/03/23	CI
Tekla Life Sciences Investors authorizes a Buyback Plan.	17/03/23	CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2023	15/02/23	CI
Tekla Life Sciences Investors Reports Earnings Results for the Full Year Ended September 30, 2022	07/12/22	CI
Tekla Life Sciences Investors Declares Distribution, Payable on December 30, 2022	15/11/22	CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 30, 2022	16/08/22	CI
Tekla Life Sciences Investors Reports Earnings Results for the Half Year Ended March 31, 2022	03/06/22	CI
Tekla Life Sciences Cuts Quarterly Dividend to $0.35 a Share From $0.39, Payable June 30 to Shareholders as of May 27	17/05/22	MT
Tekla Life Sciences Investors Declares a Distribution, Payable on June 30, 2022	17/05/22	CI
Sector Update: Financial Stocks Adding to Tuesday Gains Just Ahead of Closing Bell	22/03/22	MT
Sector Update: Financial	22/03/22	MT
Tekla Life Sciences Investors Renews Share Repurchase Program	22/03/22	MT
Tekla Life Sciences Investors authorizes a Buyback Plan.	22/03/22	CI
Tekla Life Sciences Investors announces an Equity Buyback for 12% of its outstanding shares.	22/03/22	CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2022	15/02/22	CI
Tekla Life Sciences Investors Reports Earnings Results for the Full Year Ended September 30, 2021	03/12/21	CI
Tekla Life Sciences Investors Declares Distribution, Payable on December 31, 2021	12/11/21	CI
Tekla Life Sciences Investors Declares Distribution, Payable on September 30, 2021	17/08/21	CI
Tekla Life Sciences Investors Declares Stock Distribution, Payable on June 30, 2021	18/05/21	CI
Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2021	16/02/21	CI

Chart Abrdn Life Sciences Investors

Duration

Period

More charts

Company Profile

abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.

Sector

Closed End Funds

Calendar

24/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Closed End Funds

	1st Jan change	Capi.
ABRDN LIFE SCIENCES INVESTORS	+6.02%	390M
ARES CAPITAL CORPORATION	+5.57%	12.85B
FS KKR CAPITAL CORP.	-0.15%	5.58B
SPROTT PHYSICAL URANIUM TRUST FUND	+6.69%	5.5B
PIMCO DYNAMIC INCOME FUND	+6.63%	5.24B
SPROTT PHYSICAL SILVER TRUST	+23.39%	4.84B
SPROTT PHYSICAL GOLD AND SILVER TRUST	+20.50%	4.61B
MACQUARIE KOREA INFRASTRUCTURE FUND	+2.57%	4.13B
3I INFRASTRUCTURE PLC	+7.78%	4.05B
NUVEEN AMT-FREE QUALITY MUNICIPAL INCOME FUND	-0.23%	3.28B